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Abstract
Experience with clinical liver xenotransplantation has largely involved the transplantation of livers 
from nonhuman primates. Experience with pig livers has been scarce. This brief review will be 
restricted to assessing the potential therapeutic impact of pig liver xenotransplantation in acute 
liver failure and the remaining barriers that currently do not justify clinical trials. A relatively new 
surgical technique of heterotopic pig liver xenotransplantation is described that might play a role 
in bridging a patient with acute liver failure until either the native liver recovers or a suitable liver 
allograft is obtained. Other topics discussed include the possible mechanisms for the development 
of the thrombocytopenis that rapidly occurs after pig liver xenotransplantation in a primate, the 
impact of pig complement on graft injury, the potential infectious risks, and potential physiologic 
incompatibilities between pig and human. There is cautious optimism that all of these problems 
can be overcome by judicious genetic manipulation of the pig. If liver graft survival could be 
achieved in the absence of thrombocytopenia or rejection for a period of even a few days, there 
may be a role for pig liver transplantation as a bridge to allotransplantation in carefully selected 
patients.
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Introduction
Liver transplantation offers several advantages for the treatment of patients with acute or 
fulminant liver failure or end-stage chronic liver disease, but is limited by the shortage of 
deceased human donor organs. In patients with acute liver failure, usually induced by 
chemical or viral hepatitis, the onset of disease is sudden and identification of a suitable 
donor organ is frequently not possible before permanent neurologic injury and/or death 
occurs.
In the USA, data from the United Network for Organ Sharing (UNOS)/Organ Procurement 
and Transplantation Network indicate that in 2014 the number of patients on the waiting list 
for a human donor liver was close to 16,000. Of these, only 6,729 received a transplant.1 Of 
close to 10,000 who did not receive a transplant, 3,178 died or were removed from the 
waiting list because they were too sick to undergo a major operative procedure, which is 
approximately 20% of those on the waiting list and 30% of those who did not receive a 
transplant.
Support during the critical period when the patient is in acute liver failure may be aimed at 
(i) ‘bridging’ the patient to liver allotransplantation in order to prevent irreversible cerebral 
injury, or (ii) gaining time for regeneration of a damaged native liver, if this is considered 
likely.
Potential solutions to the problem include (i) an artificial liver device, (ii) the transplantation 
of hepatocytes or (iii) hepatocyte-like expanded human stem cells, (iv) ex vivo pig or 
nonhuman primate (NHP) liver perfusion, or (v) the transplantation of a genetically-
engineered pig liver. Regenerative medicine techniques whereby a human or pig liver is 
decellularized and recelluarized with cells from the potential recipient would not be 
applicable to patients with acute liver failure. This brief review will be restricted to assessing 
the potential therapeutic impact of pig liver xenotransplantation in acute liver failure and the 
remaining barriers that currently do not yet justify clinical trials.
Clinical experience with ex vivo pig liver perfusion
Early experience has been reviewed by Hara et al.2 In the late 1960s and early 1970s, at least 
141 ex vivo pig liver perfusions were performed to treat 87 patients with liver failure, but 
then this therapeutic option was largely superseded for several years by orthotopic liver 
allotransplantation. Neurologic improvement to at least hepatic coma grade III or II has been 
documented in most patients. These clinical trials have provided valuable immunologic 
information. The data suggested that unmodified (wild-type) pig livers may be rejected less 
vigorously than other pig organs, possibly because hepatic failure is accompanied by 
diminished complement levels, although there may be additional reasons.
In a small clinical trial by Levy et al3 livers from pigs transgenic for the human complement-
regulatory proteins (regulators of complement activation, RCA), CD55 (human decay-
accelarating factor [hDAF]) and CD59, were extracorporeally perfused in 2 patients with 
acute hepatic failure for 6.5h and 10h, respectively, as bridging to successful 
allotransplantation. The histopathological findings in these cases were similar to those 
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described with nontransgenic pig livers. Of interest, the authors made no mention of whether 
thrombocytopenia developed.
Clinical experience with pig liver xenotransplantation
Following the development of techniques of vascular anastomosis at the beginning of the 
20th century, organ xenotransplantation became possible. Most of the early attempts at 
clinical organ xenotransplantation used NHP species as sources of the organ (reviewed in 2), 
although there were a few attempts using the pig and other nonprimate mammals, but 
without significant success.4–6
Only 1 of these experiences related to the transplantation of a pig liver. In 1993, Makowka 
and his colleagues performed the only heterotopic pig liver xenotransplant, with the aim of 
performing orthotopic allotransplantation when a human donor became available, at which 
time the auxiliary pig liver would have been removed.7,8 The patient was a 26-year-old 
woman with a 14-year history of autoimmune hepatitis who was admitted to hospital with 
grade III encephalopathy. Hepatitis C was detected serologically. She was listed with the 
UNOS at the highest priority. Despite aggressive medical therapy, the patient continued to 
deteriorate, with increasing encephalopathy and coagulopathy.
A wild-type (genetically-unmodified) pig liver was transplanted heterotopically. Before 
transplantation, circulating natural anti-pig antibodies were removed by plasmapheresis and 
ex vivo perfusion of the donor pig kidneys. After transplantation, the liver xenograft clearly 
functioned, as documented by bile production, stabilization of prothrombin levels, and 
reduction in the levels of lactic acid and the enzymes aspartate aminotransferase and alanine 
aminotransferase. Unfortunately, this did not result in any improvement in the neurologic 
status of the patient, who died after 34 hours from irreversible brain damage.
Despite the removal of >90% of the recipient’s natural xenoantibodies prior to 
transplantation, antibody rapidly returned and was associated with complement-mediated 
injury of the graft. A liver biopsy obtained 3 hours posttransplantation showed deposition of 
antibody and complement components, and endothelial swelling, suggesting early graft 
rejection. At the time of death, the pig liver showed thrombosis and ischemic necrosis. 
Importantly, however, no mention was made as to whether thrombocytopenia was 
documented, as seen in pig-to-NHP models (see below). Nevertheless, this experience 
demonstrated the ability of a pig liver to function, at least temporarily, in a human recipient 
and to provide some metabolic support during acute liver failure.
Experimental pig liver xenotransplantation in nonhuman primates
There have been several reports of liver xenotransplantation between species of NHPs 
[reviewed in 2–42], but, for a number of reasons,9 it is very unlikely that NHPs will be 
acceptable as sources of livers for clinical transplantation in the future. The pig-to-NHP 
model is increasingly being investigated to assess strategies aimed at advancing towards 
clinical xenotransplantation (Figure 1).
In untreated NHPs, wild-type pig livers have generally undergone early antibody-mediated 
rejection (intravascular thrombosis, hemorrhagic necrosis, endothelial cell injury, deposition 
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of IgM, IgG, C3), though no intravascular fibrin aggregation is seen (Figure 2A). For 
example, Ramirez et al reported 3 baboons that survived for <12 hours and showed features 
of hyperacute rejection (Table 1).10,11 Subsequently, Ekser et al provided sequential data on 
the development of hyperacute rejection in this model.12
When genetically-engineered pigs have been the source of the liver, the results have 
significantly improved. In the same series of experiments by Ramirez et al10,11 2 baboons 
transplanted with livers from pigs transgenic for the human RCA, CD55 (human decay-
accelerating factor, hDAF) survived for 4 and 8 days, respectively (Table 1). Neither liver 
xenograft demonstrated histopathologic features of hyperacute rejection. This study 
indicated that, when hyperacute rejection is abrogated by the expression of hCD55, the 
porcine liver can maintain reasonable levels of coagulation factors and protein in the baboon 
for up to 8 days, although factors II, VII, and X decreased significantly. The authors 
confirmed studies in rodents that established that the recipient progressively acquires the 
protein profile of the donor species.13–15 In a subsequent brief report by this group, livers 
from pigs transgenic for 2 hRCAs (CD55, CD59) and H-transferase survived only 13–24 
hours in baboons.16
Ekser et al reported their experience of orthotopic pig liver xenotransplantation in baboons 
with grafts from α1,3-galactosyltransferase gene-knockout (GTKO) pigs or GTKO pigs 
transgenic for the human RCA, CD46 (GTKO/hCD46) and a clinically applicable 
immunosuppressive regimen (Table 1).12,17 Profound thrombocytopenia developed within 
one hour posttransplantation (Figure 3A), which resulted in spontaneous hemorrhages in 
various native organs and in the liver graft, limiting recipient survival to a maximum of 7 
days. However, throughout much of this time, hepatic function was documented near-normal 
to normal (as assessed by liver enzymes, coagulation factors, coagulation assays, and 
production of porcine-specific proteins).18 There was no definitive humoral and cellular 
rejection (as documented on biopsies taken at 2 hours or at the time of euthanasia or death 
(at 4–7 days posttransplant) (Figure 2B).
Kim et al reported GTKO Massachusetts General Hospital (MGH) miniature swine 
orthotopic liver xenotransplantation in baboons with an intensive immunosuppressive 
regimen (Table 1).19 Their initial 3 cases survived 6, 8, and 9 days, respectively. The 6-day 
survivor died of spontaneous hemorrhage associated with profound thrombocytopenia, as 
observed by Ekser et al.12 In the 8-and 9-day survivors, loss of platelets was ameliorated to 
some extent by blocking fibrinolysis by the administration of aminocaproic acid. Although 
thrombocytopenia was marginal (platelet counts remained between 40–50,000/mm3), the 
baboons suffered severe blood loss and sepsis.
The mechanisms by which platelet aggregation and phagocytosis occurred were investigated 
in vitro.20 Pig hepatocytes, liver sinusoidal endothelial cells, and aortic endothelial cells all 
induced moderate aggregation of baboon platelets (but not of pig platelets), and sinusoidal 
endothelial cells were shown to phagocytose baboon platelets (as demonstrated previously 
with human platelets in an ex vivo perfusion model by Tector and his colleagues.21–24 
Phagocytosis could be significantly reduced by certain agents, e.g., aurintricarboxylic acid 
(which blocks von Willebrand Factor [vWF]).
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Yeh et al went on to assess the effect of maintaining the recipient liver in situ and 
transplanting the pig liver heterotopically.25 Although thrombocytopenia developed as 
before, the presence of baboon coagulation factors prevented severe spontaneous 
hemorrhage from occurring. However, features of thrombotic microangiopathy and ischemia 
developed in the graft (as seen in pig hearts and kidneys), resulting in graft failure in 2 cases. 
Survival of the 3 grafts or recipients was limited to 6, 9, and 15 days, respectively, with 
sepsis being a major cause of death.
Recently, Navarro-Alvarez et al reported 7 further cases (6 new, 1 historical) of orthotopic 
GTKO pig-to-baboon liver xenotransplantation,26 in which they sought to determine the 
effects of the administration of human coagulation factors (Table 1). Graft and recipient 
survival was 1 and 3 days (with bolus administration) and 5–7 days (with continuous 
administration), which was not different from survival of a historical control baboon (6 
days). Platelet counts were maintained, but the baboons quickly developed large vessel 
thrombosis and thrombotic microangiopathy. Several deaths were from infection.
The most recent report 27 documented 25-day survival of a GTKO pig liver graft in a baboon 
treated with a human prothrombinase concentrate complex. Immunosuppressive therapy 
included induction with antithymocyte globulin and cobra venom factor, with maintenance 
with belatacept, tacrolimus, and methylprednisolone. Abnormalities of liver function tests on 
day 7 were presumed to be associated with rejection, but were reversed by a course of 
steroid pulses. Early thrombocytopenia began to recover by day 11 and was maximal on day 
21 (614,000/mm3) without the need for platelet transfusions. Euthanasia was necessary on 
day 25 from the development of plantar ulcerations (associated with peripheral edema), 
progressive cholestasis, hemolysis, and a rising direct bilirubin. The liver showed no 
macroscopic features of necrosis with all vessels free of thrombus. This report provides 
encouragement that a pig liver graft might maintain life in a patient with fulminant hepatic 
failure until either recovery of the native liver occurs (if the pig liver had been transplanted 
heterotopically) or until an allograft becomes available.
Another recent experience has been gained by Dou’s group from Xi’an, China, who inserted 
a left liver lobe from GTKO Wu Zhishan miniature swine as auxiliary grafts into Tibetan 
monkeys (Table 1).28 Their innovative surgical technique is illustrated in Figure 4. Although 
it requires native splenectomy, the Xi’an technique has the advantage that none of the native 
liver needs to be excised as the graft fits comfortably into the splenic fossa. (Ekser et al17, 
Navarro-Alvarez et al26, Yeh et al25, and Shah et al27 all performed splenectomy in order to 
reduce thrombocytopenia. However, whether splenectomy is immunologically beneficial to 
the outcome is uncertain, but there was no definitive evidence for this in the early studies of 
pig heart or kidney xenotransplantation [reviewed in 29.)
Of interest, the surgical technique introduced by the Xi’an group was first used successfully 
in clinical liver allotransplantation in 2007 in a patient with Wilson’s disease, splenomegaly, 
and hypersplenism, and has since been employed in a further 14 patients, using both living 
donors (excising segments 2 and 3) and split livers from deceased (donation after cardiac 
death) donors (Dou K-F, et al, unpublished). Following the work of Olausson et al,30 in 1 
patient with >90% panel-reactive antibodies (PRA) in need of kidney transplantation, the 
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donor liver graft was inserted heterotopically before the donor kidney with the intention of 
preventing antibody-mediated hyperacute rejection of the kidney, which it did successfully.
In their xenotransplantation studies, graft survival, as defined by various parameters of 
hepatic function, extended between 2 and almost 14 days, although the presence of the 
native recipient liver would have been beneficial. In none of the 3 monkeys was the fall in 
platelet count during the first 24 hours as dramatic or as profound (Figure 3B) as in the 
experience of others (Figure 3A).17,19,25 In the longest-surviving monkey, although the 
platelet count remained at approximately 50,000/mm3 by the end of the experiment (day 14) 
(Figure 3C), whether this difference can be accounted for by the fact that the recipient was a 
Tibetan monkey rather than a baboon, or that the organ-source pig was a Wu Zhishan 
miniature swine remains uncertain, but needs to be explored.
The study provided further valuable data on the coagulation disorders that develop following 
pig liver transplantation in NHPs. The authors demonstrated that early activation of recipient 
tissue factor is largely responsible for coagulation dysregulation (supporting the studies by 
Lin et al,31,32 in part related to incompatibility between pig tissue factor pathway inhibitor 
(TFPI) and primate tissue factor, which results in the inefficient inhibition of recipient tissue 
factor.33 Accompanying in vitro studies indicated that the overexpression of human TFPI by 
pig bone marrow-derived mesenchymal stromal cells inhibited clotting, which is an 
observation that may be of potential therapeutic importance and warrants further 
investigation.34,35
From the above combined studies, we can tentatively conclude that early after 
transplantation of a liver from a genetically-engineered pig, microscopic and 
immunohistochemical examination of a liver biopsy has been almost normal, with minimal 
(patchy) or no deposition of IgM, IgG, C3, C4d, and C5b-9. At necropsy some days later, 
some livers showed macroscopic changes consistent with cholestasis, except for some 
patchy dark areas which microscopically showed hemorrhagic necrosis, platelet-fibrin 
thrombi, monocyte/macrophage margination, and vascular endothelial cell hypertrophy 
(Figure 2C).12,28,36–38 No cell infiltration was seen. Confocal microscopy has confirmed 
tissue factor expression on platelets, and platelet and platelet/leukocyte aggregates in liver 
sinusoids. The minimal or absent deposition of immunoglobulin or complement fractions 
and absence of a cellular infiltrate suggest that neither antibody- nor cell-mediated rejection 
plays a major role in injury to genetically-engineered pig liver grafts. Platelet loss and 
platelet/leukocyte aggregation would appear to be a major problem.21,39 However, if the 
native liver remains in situ, the production of primate coagulation factors leads to the 
development of thrombotic microangiopathy in the graft, resulting in ischemic injury and 
graft destruction (just as in pig heart and kidney xenografts).
Considerable progress in pig organ xenotransplantation into NHPs has been made in the past 
few years, largely through the availability of pigs with an increasing number of genetic 
manipulations.40 However, these advances have largely been confined to heart and kidney 
xenotransplantation,41–48 as the barriers associated with pig lung 41 and liver 2,42,43 
xenotransplantation are rather more complex.
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Investigation of the mechanisms of platelet loss
The studies summarized above have identified certain barriers specific to the liver that need 
to be overcome. The major outstanding problem preventing successful long-term pig liver 
xenotransplantation is the rapid loss of platelets from the recipient within minutes or hours 
of the transplant. Evidence has been presented to indicate that (i) primate platelets are 
phagocytosed by pig liver macrophages (Kupffer cells) and sinusoidal endothelial 
cells,20–23,44 or (ii) may be lost in platelet-leukocyte aggregates in the graft and in certain 
recipient organs.20,39
Potential factors that may contribute towards the phagocytosis include (i) the activity of the 
asialoglycoprotein receptor-1 (ASGR1, present on sinusoidal endothelial cells) (Figure 5) 
and the macrophage antigen complex-1 (CD11b/CD18; Mac-1, a surface integrin receptor 
on Kupffer cells),22,44 (ii) interspecies incompatibility and phagocytic dysregulation in the 
porcine signal regulatory protein-alpha (SIRPα)/human CD47 pathway (Figure 6),41,45–47 
and (iii) upregulation of tissue factor expression on activated donor liver sinusoidal 
endothelial cells activated by the immune response, as well as on recipient platelets and 
mononuclear cells. Furthermore, ASGR1 is expressed on aortic and systemic arterial 
vascular endothelium in pigs and this may play a role in binding and phagocytosis of human 
platelets.48 There may therefore be multiple factors involved, but specific genetic 
engineering of the organ source pig may negate this problem.
Although pigs naturally deficient in vWF have been available for some time,49–53 they are 
extremely difficult to work with in surgical research and, furthermore, do not resolve the 
problems faced in xenotransplantation. As pig vWF activates recipient primate platelets,54,55 
an alternative approach might be to generate pigs in which pig vWF has been knocked out 
and replaced with human vWF,41 but such pigs are not yet available.
In addition to the reported loss of platelets in NHPs, the ex vivo perfusion of a pig liver with 
human blood demonstrated that pig macrophages continuously phagocytosed human 
erythrocytes;56,57 this was unrelated to antibody binding and complement activation, but was 
associated with direct recognition of erythrocytes by pig Kupffer cells.58,59 A pig liver 
removed approximately 1 unit of human erythrocytes from the circulation every 24 hours. 
Phagocytosis of recipient erythrocytes has not been documented in most studies in NHPs, 
suggesting that the expression of N-glycolylneuraminic acid (NeuGc) on pig erythrocytes 
and the production of anti-NeuGc antibodies in humans (but not in NHPs which, like pigs, 
express NeuGc) may be playing a role 60 (reviewed in 61). Pigs in which the gene for the 
enzyme that adds NeuGc to underlying carbohydrate chains has been deleted have recently 
become available,62 and Butler et al63 showed that a GTKO/NeuGc-knockout pig liver 
significantly reduced xenogeneic consumption of human platelets in an ex vivo perfusion 
study.
The impact of pig complement on the liver graft
Despite these negative aspects of pig liver xenotransplantation, there may be some 
advantages in comparison with xenotransplantation of the pig heart or kidney. As the liver is 
the major site of synthesis of complement proteins, except for C1q, factor D, properdin, and 
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C7, impaired hepatic synthetic function contributes to complement deficiency in patients 
with hepatic disease.64–69 The level of membrane attack complex activity may be much 
lower than that seen in healthy subjects, reducing the possibility of early graft injury.
Furthermore, after pig liver transplantation in humans (or NHPs), the graft will produce pig 
complement. In vitro studies have indicated that (i) in the presence of human antibodies, pig 
complement is associated with less lysis of pig cells than human complement (and thus may 
be associated with less graft injury), (ii) lysis by pig complement of GTKO pig cells is 
significantly less than of wild-type pig cells, and (iii) the expression of a human RCA on the 
pig cell can reduce pig complement-induced lysis of the cells.43 Rees and his colleagues also 
provided evidence suggesting that human RCAs will successfully inhibit porcine 
complement.59 In ex vivo liver perfusion with human blood, survival of hCD55 (hDAF) 
transgenic pig livers for up to 72 hours indicated that a pig liver expressing both pig and 
human RCAs may provide some protection from injury by pig complement.56,57 Although 
human complement components will continue to be produced by various recipient cells, the 
transgenic expression of a hRCA in the graft should be protective.
Independent of the low complement levels seen in patients with hepatic failure, numerous 
studies have shown that the liver is more resistant than other solid organs to injury from 
preformed graft antibodies.70–73 In some studies, human serum caused significantly less 
cytotoxicity when incubated with porcine hepatic sinusoidal endothelial cells than with 
porcine aortic endothelial cells (25% vs 72%).69 This relative resistance to injury could 
possibly be related to the liver’s ability to clear soluble immune complexes,69 or to less 
binding of human IgM and IgG to porcine hepatic sinusoidal endothelial cells when 
compared to aortic endothelial cells (on flow cytometry), suggesting lower expression of 
antigens.74
The liver complement levels in patients with liver failure and the possible resistance of the 
sinusoidal endothelium to injury combine to contribute to protection of the liver from 
antibody-mediated rejection. Serum from patients with hepatic failure caused significantly 
less lysis of both porcine aortic (38% versus 72%) and hepatic sinusoidal (9% versus 25%) 
endothelial cells.69
The potential of sensitization to pig antigens
If a pig liver is employed to bridge the patient to allotransplantation, will exposure to pig 
tissues result in the production of anti-pig antibodies that might cross-react with 
alloantigens, thus preventing or being detrimental to allotransplantation? Studies of cross-
reactivity between anti-species antibodies and/or sensitized T cells are few (reviewed in 75), 
but there has been little evidence for the development of cross-reactive cytotoxic antibodies 
or activated T cells that might mediate humoral or accelerated cellular rejection of a 
subsequent allograft.76–78
In this respect, the 2 patients who underwent successful liver allotransplantation following 
relatively transient bridging by ex vivo hemoperfusion of porcine livers (see above) did not 
develop anti-HLA antibodies.3 Bridging with a bioartificial liver, which incorporated porcine 
hepatocytes, has also been followed by successful liver allotransplantation.79 A liver 
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allograft transplanted after a bridging pig xenograft would therefore not appear to be at 
increased risk of either humoral or cellular rejection.
Potential infectious risks
The risks of the transfer of microorganisms with the pig organ to the human recipient and, 
more importantly, of the transfer of a porcine infectious agent to the community are now 
considered to be small.80–84 Indeed, the use of animal organs might have some advantages 
with regard to recurrence of disease, such as viral hepatitis, as some viruses are species-
specific. For example, following pig-to-baboon organ transplantation, porcine 
cytomegalovirus has not been documented to infect the host baboon, and baboon 
cytomegalovirus has not been seen to infect the transplanted pig organ.85,86 Nevertheless, 
porcine endogenous retroviruses (PERVs) are present in the genome of every pig cell, and 
would therefore be transplanted with the organ. Although the risk of PERVs causing any 
disease process in the recipient or in the community is considered low,83,84,87 using the new 
CRISPR/Cas9 technology, it is now possible to render pig cells PERV-negative 88 and so it is 
likely that PERV-negative pigs will become available in the future, if this is believed to be 
essential.
Most aspects of physiologic compatibility between pig and human have been sparsely 
investigated or not investigated at all, in part because it is difficult to accurately assess true 
hepatic function in the presence of an ongoing immune response.89–92 Nevertheless, 
significant incompatibilities between pig and human hepatic function are almost certain to 
be present, though some of these may be relative rather than absolute hurdles. If a function, 
e.g., the synthesis of a key protein, is found to be essential, and that function cannot be 
achieved by the pig liver, genetic modification of the source pig can be carried out to 
produce its human protein counterpart.
Conclusions
Attempts at liver xenotransplantation can best be justified if the patient will die rapidly 
without transplantation. Although prolonged function (i.e., weeks or months) of a 
transplanted pig liver in a primate cannot yet be guaranteed, in rapidly-deteriorating patients 
with acute liver failure, liver xenotransplantation (particularly if a GTKO/hRCA pig liver is 
implanted), could probably be considered as a short-term (days) bridge to allotransplantation 
as long as thrombocytopenia and coagulopathy can be prevented.93,94 Auxiliary liver 
xenotransplantation might allow recovery of the native organ. Orthotopic pig liver 
xenotransplantation would be preferable if the state of the native liver was increasing the risk 
of mortality to the patient, or if no recovery of the native liver is anticipated. 95
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Figure 1. 
Time-line in experimental pig liver xenotransplantation in NHPs.
Abbreviations: a-CD154 = anti-CD154 monoclonal antibodies; ALG = antilymphocyte 
globulin; ATG = antithymocyte globulin; Aza = azathioprine; Bela = belatacept; BM = bone 
marrow; Cs = corticosteroids; CsA = cyclosporine; CVF = cobra venom factor; CyP = 
cyclophosphamide; FK = tacrolimus; Gal abs = extracorporeal anti-Gal antibody adsorption; 
GTKO = 1,3-galactosyltransferase gene-knockout; hCD46 = expression of the human 
regulator of complement, hCD46; hCD55 = expression of the human regulator of 
complement, CD55; HLT = heterotopic liver transplantation; HT = H-transferase; LoCD2b = 
anti-CD2 monoclonal antibody; MMF = mycophenolate mofetil; OLT = orthotopic liver 
transplantation; WBI = whole body irradiation; WT = wild-type.
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Figure 2. 
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Histopathology of (A) hyperacute rejection (<24 hours) in a wild-type pig liver transplanted 
orthotopically into a baboon, (B) a GTKO/hCD46 orthotopic pig liver graft in a baboon that 
survived for 6 days, and (C) a pig left liver lobe graft in a Tibetan monkey that survived for 
14 days
(A) WT pig-to-baboon liver xenotransplantation at 1 h (x200). Severe hepatocellular 
vacuolar change, focal hepatocyte necrosis, and few thrombi.
(B) Vacuolar hepatocellular cytoplasmic change with minimal hepatocellular necrosis on 
postoperative day 6 (x200).
(C) The graft shows some lymphocyte infiltration in the portal area, but no major features of 
antibody-mediated or cellular rejection (x100).
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Figure 3. 
Platelet counts (A) after GTKO/hCD46 orthotopic pig liver transplantation in baboons (n=6) 
that survived from 4–7 days, and (B) after a GTKO Wu Zhishan miniature swine heterotopic 
left liver lobe transplant in Tibetan monkeys (n=3, mean ±SD) within the first 48 hours, and 
(C) in the Tibetan monkey that survived for 14 days. (A is reproduced with permission from 
Ekser et al. Transplantation 2010;90:483–493; B is reproduced with permission from Ji H, et 
al.28
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Figure 4. 
Surgical technique of pig left liver lobe transplantation in Tibetan monkeys. After native 
splenectomy, the pig liver graft was placed in the splenic recess. The recipient’s left renal 
vein was divided, the distal end being anastomosed to the graft portal vein, and the proximal 
end to the graft hepatic vein. The graft hepatic artery was anastomosed end-to-end to the 
recipient splenic artery (using a microvascular technique with an operating microscope). 
After reperfusion, the bile duct was drained through the abdominal wall to allow 
measurement of bile drainage. (Using the same technique in clinical cases of 
allotransplantation, the bile duct is drained into a Roux-en-Y jejunal loop.)
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Figure 5. 
Potential mechanism of human platelet phagocytosis by pig livers - 1. Human platelets may 
be selectively phagocytosed by ASGR1-expressing cells, e.g., liver sinusoidal endothelial 
cells, as human platelets express higher levels of Galβ1,4N-acetylglucosamine 
(Galβ1,4GlcNAc).
Cooper et al. Page 23
Transplantation. Author manuscript; available in PMC 2017 October 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 6. 
Potential mechanism of human platelet phagocytosis by pig livers - 2. Schematic 
representation of CD47-SIRPα (signal regulatory protein-alpha) interaction in relation to 
natural expression of SIRPα on pig Kupffer cells; (Left) In the organ-source pig, there is a 
normal inhibitory signal of pig CD47 (in this example expressed on platelets) that is 
recognized by porcine SIRPα; (Center) After pig liver xenotransplantation, there could be a 
lack of recognition of human CD47 by pig SIRPα, resulting in phagocytosis of human 
platelets; (Right) Transgenic expression of human SIRPα on pig Kupffer cells would result 
in recognition of human CD47 on human platelets, thus inhibiting phagocytosis. 
(Reproduced with permission from Ekser et al. Expert Rev. Clin. Immunol. 2012;8:621–
634)
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